Aim for zero: Most people on HEMLIBRA didn’t have any bleeds that needed treatment with additional therapy

Percentage of people with zero bleeds in our studies*

WITHOUT factor VIII inhibitors: HAVEN 3 Study (adults and young adults)

WITH factor VIII inhibitors: HAVEN 1 Study (adults and young adults)

WITH factor VIII inhibitors: HAVEN 2 Study (children)

WITH or WITHOUT factor VIII inhibitors: HAVEN 4 Study (adults and young adults)

*The need to treat was determined by the individual or the trial physician. 
Individuals did not receive prophylactic bypassing therapy.

Adults: 18 years or older.
Young adults (adolescents): 12 to less than 18 years.
Children: less than 12 years.
People who were included in HAVEN 1 and HAVEN 3 were in the study for at least 24 weeks. People in HAVEN 2 were in the study for at least 52 weeks. People in HAVEN 4 were in the study for at least 24 weeks.
The median time on HEMLIBRA was 31 weeks (HAVEN 3), 29 weeks (HAVEN 1), 58 weeks (HAVEN 2), and 26 weeks (HAVEN 4). A median is a numeric middle. That means that in a list of numbers, the median is the number in the middle.

Click below to explore more data

Bleed Reduction Studies

Studies in Children

More than 6100 people have been treated with HEMLIBRA worldwide

Ready to talk to your doctor? Download the doctor discussion guide to start the conversation.

Watch HEMLIBRA Stories

See patients talk about their experiences with HEMLIBRA

Talk to Your Doctor

The Doctor Discussion Guide can help get the conversation started